n South African Journal of Child Health - The cost of nephroblastoma treatment in South Africa : a very cost-effective investment with guidelines for the rest of Africa : research
|Article Title||The cost of nephroblastoma treatment in South Africa : a very cost-effective investment with guidelines for the rest of Africa : research|
|© Publisher:||Health and Medical Publishing Group (HMPG)|
|Journal||South African Journal of Child Health|
|Affiliations||1 Stellenbosch University, 2 Stellenbosch University, 3 Stellenbosch University, 4 South African Medical Research Council and 5 University of the Free State|
|Publication Date||Nov 2014|
|Pages||128 - 132|
Background. Nephroblastoma is one of the most common childhood malignancies in Africa, but with a survival rate significantly lower than in developed countries. In African countries with a small gross domestic product (GDP) per capita, the cost of treating nephroblastoma may be prohibitive.
Objectives. To determine the direct costs of treatment of nephroblastoma in South Africa (SA) and to propose a more cost-effective approach to investigations and treatment for the disease in Africa.
Methods. Data from 2000 to 2010 from two SA paediatric oncology units were retrospectively analysed. The costs included investigations, chemotherapy and radiotherapy, comparing early- v. advanced-stage disease. In both units, the nephroblastoma International Society of Paediatric Oncology (SIOP) protocol was used.
Results. Stage I disease was the most common, followed by stage IV. The total cost of diagnosis, staging and treatment of stage I disease was ZAR9 304.97 (EUR882.80 or USD1 093.40), compared with a five-times higher cost for stage IV (ZAR48 293.62 (EUR4 581.9 or USD5 674.9)). Treating one patient averted more than 32 disability-adjusted life years. The investigation and treatment of early- and advanced-stage disease is very cost-effective when compared with the local GDP per capita.
Conclusion. The cost of investigation and treatment of nephroblastoma remains a challenge everywhere, but especially in Africa. However, it is a very cost-effective disease to treat and children in Africa should not be denied treatment.
Article metrics loading...